BackAclaris Therapeutics Overview
Aclaris Therapeutics Inc

Aclaris Therapeutics Target Price

See Aclaris Therapeutics's analyst price targets ($10) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.17

Average Target Price

$10.0062.1% upside

1 analysts in the last 4 months

High: $10 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-01Canaccord GenuityEdward Nash$1062.1% upsideOpen
2026-05-05Piper SandlerBiren Amin$1178.3% upsideOpen
2026-05-05Guggenheim$1294.5% upsideOpen
2026-04-29WedbushMartin Fan$1062.1% upsideOpen
2026-04-16UBS$1062.1% upsideOpen
2026-01-30Craig-HallumAdam Vogel$1062.1% upsideOpen
2024-11-19BTIGJulian Harrison$829.7% upsideOpen
2024-11-19JefferiesRoger Song$713.5% upsideOpen
2024-11-06Stifel NicolausAlex Thompson$351.4% downsideOpen
2022-12-01Goldman Sachs$25305.2% upsideOpen

Aclaris Therapeutics (ACRS) FAQ

Aclaris Therapeutics posts a target price of $10. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $10 for ACRS means covering analysts, on average, see the stock 62.1% upside of $6.17 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ACRS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Aclaris Therapeutics's other metric pages and overview cover the third.

Judging Aclaris Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $10 here, then scan peer and history charts to see if the gap is persistent.